IDiyas

For the Inventor, By the Inventor

Thousand Oaks, CA, United States of America

Shon Booker

USPTO Granted Patents = 38 


 

Average Co-Inventor Count = 13.6

ph-index = 15

Forward Citations = 582(Granted Patents)


Location History:

  • Newbury Park, CA (US) (2006)
  • Thousand Oaks, CA (US) (2005 - 2024)
  • Sherman Oaks, CA (US) (2016 - 2024)

Company Filing History:

goldMedal37 out of 1,970 
 
Amgen Inc.
 patents
silverMedal1 out of 1 
 
Amgem Inc.
 patent
bronzeMedal1 out of 124 
 
Teijin Pharma Limited
 patents
where one patent can have more than one assignee

Years Active: 2005-2025

where 'Filed Patents' based on already Granted Patents

38 patents (USPTO):
1. 12440491 - KRAS G12C inhibitors and methods of using the same (2025-10-14),
2. 12083121 - Substituted piperazines as KRAS G12C inhibitors (2024-09-10),
3. 11993597 - Inhibitors of KRAS G12C and methods of using the same (2024-05-28),
4. 11905281 - KRAS G12C inhibitors and methods of using the same (2024-02-20),
5. 11845760 - PRMT5 inhibitors (2023-12-19),
6. 11766436 - KRAS G12C inhibitors and methods of using the same (2023-09-26),
7. 11306087 - Inhibitors of KRAS G12C and methods of using the same (2022-04-19),
8. 11285156 - Substituted piperazines as KRAS G12C inhibitors (2022-03-29),
9. 11285135 - KRAS G12C inhibitors and methods of using the same (2022-03-29),
10. 11096939 - KRAS G12C inhibitors and methods of using the same (2021-08-24),
11. 11090304 - KRAS G12C inhibitors and methods of using the same (2021-08-17),
12. 10640504 - Inhibitors of KRAS G12C and methods of using the same (2020-05-05),
13. 10532042 - KRAS G12C inhibitors and methods of using the same (2020-01-14),
14. 10519146 - KRAS G12C inhibitors and methods of using the same (2019-12-31),
15. 9365522 - Pyrazole amide derivative (2016-06-14),

Title: The Innovative Journey of Shon Booker from Thousand Oaks, CA

Introduction: Shon Booker, a prolific inventor based in Thousand Oaks, CA, has made significant contributions to the field of pharmacology with a remarkable portfolio of 35 patents. His groundbreaking work includes inventions such as KRAS G12C inhibitors and PRMT5 inhibitors, revolutionizing the treatment landscape for various disorders, particularly cancer.

Latest Patents:

Shon Booker's latest patents showcase his dedication to advancing medical science. The first patent revolves around KRAS G12C inhibitors, offering a novel approach to treating pancreatic, colorectal, and lung cancers. These inhibitors have shown promising results in combating these challenging diseases. The second patent focuses on PRMT5 inhibitors, which hold potential in treating proliferative, metabolic, and blood disorders. The compounds developed by Booker have opened new possibilities for therapeutic interventions.

Career Highlights:

Shon Booker's career is closely intertwined with Amgen Inc., a renowned biotechnology company at the forefront of innovation. His association with Amgen Inc. has been instrumental in translating his research into tangible solutions for complex medical conditions. Booker's relentless pursuit of excellence has earned him recognition as a key player in the pharmaceutical industry.

Collaborations:

In his quest for scientific excellence, Shon Booker has collaborated with esteemed colleagues such as Tae-Seong Kim and Longbin Liu. Together, they have synergized their expertise to drive forward cutting-edge research projects and develop life-changing inventions. The collaborative spirit exhibited by Booker and his coworkers underscores the importance of teamwork in pushing the boundaries of science.

Conclusion:

Shon Booker's ingenuity and commitment to improving patient outcomes stand as a testament to his remarkable legacy. Through his innovative patents and collaborative efforts, he has cemented his position as a visionary inventor shaping the future of pharmacology. As he continues to push the boundaries of scientific discovery, the world eagerly anticipates the next breakthrough from this trailblazing inventor from Thousand Oaks, CA.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…